Microbioz India, February 2024 | 51 This webinar gives senior managers in organizations with laboratories, the knowledge to ask the tough questions and uncover which is the right choice for them. Developed using Autoscribe’s many years of industry experience, it provides a balanced view of the benefits and limitations of on-premise and cloud solutions. Presented by Samuel Clark, Technical Sales Manager for North America at Autoscribe Informatics, it draws on recent experience in implementing laboratory informatics solutions across multiple industries from pharmaceutical and medical devices, to environmental, food and drink. Topics covered include: 1. Why use the Cloud? 2. What does “Cloud” even mean? 3. How secure is a cloud system? 4. What happens to your data? 5. How can you integrate instruments and other systems? 6. What is the disaster recovery options? As a learning aid, this webinar is essential viewing for those making the hard choices of where to keep your main corporate asset – your data. It recognizes there are trade-offs to make, and often no perfect answers, yet arms the audience with the facts to drive the right decision for their organization. After this webinar viewers will be able to decide which choice is right for their organization. Either way, since Autoscribe supports both on-premise and cloud deployments with their Matrix Gemini LIMS, the choice is entirely up to the needs of each client. Aptamer Group signs material agreement with genetic medicines company Story source/Credit: Aptamer Group Optimer binders will be developed to support targeted genetic medicines to specific cell types ptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces that it has entered into a material agreement with a biotechnology company developing genetic medicines. Under the terms of the agreement, Aptamer Group will use its proprietary platform to discover Optimer binders to enable the specific targeting of genetic medicines to specific cell types. Aptamer Group will receive up to £553,000 in development fees for discovering and developing the Optimer binders. Work is expected to commence shortly subject to receiving target materials from the customer and is expected to be completed within the current financial year. Optimer binders are a novel class of molecules for selectively targeting new biomarkers and tissues. Optimers are fully synthetic oligonucleotide molecules that offer a controlled development process, delivering high affinity and highly selective binders, which makes them attractive candidate molecules for drug delivery. A Product Launches
Microbioz India, February 2024 | 52 The smaller size of Optimers allows for improved tissue penetration, enabling effective therapeutic delivery, while the ability to control Optimer conjugation to therapeutic payloads allows precision in therapeutic development and dosing of payloads. Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: “This project builds on the work we have been doing in drug delivery since being refunded and supports the need for new delivery modalities within the genetic medicines space. Targeting oligonucleotide therapeutics beyond hepatocytes remains a challenge across the industry; we believe the properties of Optimers make them suitable for developing precision-guided therapies and that Optimer-targeted therapies may represent the next stage in targeted drug delivery.” About Aptamer Group plc Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers. Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion. Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royaltybearing licenses. Thermo Fisher Scientific Launches New Ion Chromatography Instrument to Improve Reliability, Efficiency, and Functional Adaptability for Labs Story source/Credit: Thermo Fisher Scientific New Thermo Scientific Dionex Inuvion Ion Chromatography System streamlines ion analysis and expands analytical testing capabilities for ionic and small polar compounds o support a wider range of ion chromatography analysis with one instrument, Thermo Fisher Scientific Inc., has launched the Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis. T Product Launches
Microbioz India, February 2024 | 53 As safety concerns increase around our environment, particularly our food and water supply, scientists will require versatile and sensitive instruments for adequate testing and analysis. Aligned with Thermo Fisher’s mission to enable our customers to make the world healthier, cleaner and safer, the Dionex Inuvion IC system equips environmental, industrial, municipal water, and food and beverage labs with the necessary equipment to determine ionic contaminants in water. The technology also helps identify corrosive contaminants in oil and gas, as well as provide quality assurance and quality control of small ionic compounds in food, beverage, and pharmaceuticals. The Dionex Inuvion system helps meet labs’ needs to operate more efficiently with easily configurable workflows and a small footprint. The flexible platform can be tailored to meet current analytical requirements and helps extend IC capabilities to adapt to changing sample types and workflow requirements in the future more easily and costeffectively. “As the originator of ion chromatography, we continue to lead innovation in all areas of instrumentation and column chemistry to meet our customers’ growing needs for better resolution, faster results, and intuitive lab experience,” said Lidija Raicevic, vice president and general manager of Ion Chromatography and Sample Preparation at Thermo Fisher Scientific. “The Dionex Inuvion system is built on years of expertise and this new system will provide enhanced capabilities to labs of all sizes while helping streamline our IC portfolio so labs can more easily find the technology that is best for their needs.” The Dionex Inuvion IC system features new advanced pump technology that improves speed, quality, and reproducibility; operator-friendly engineering to enhance the operator experience; and user-installable accessories that extend its capabilities and ultimately help achieve the highest quality results. Developing a novel norovirus vaccine candidate with INTEGRA pipettes Story source/Credit: INTEGRA Biosciences AG HilleVax wins EVOLVE manual pipettes and GRIPTIPS pipette tips, enhancing its laboratory resources to help drive vaccine research forward. INTEGRA Biosciences has awarded 50 EVOLVE manual pipettes, GRIPTIPS®pipette tips worth US $1000 and various lab accessories to HilleVax, helping to advance its pioneering research into norovirus vaccine development. The prize – part of the recent ‘INTEGRA supports start-ups’ competition, which concluded in April 2023 – will provide the company with the resources needed to accelerate its vaccine candidate to licensure. illeVax was founded to develop novel vaccines as a powerful means of addressing health inequalities and equalizing care for patients around the world. The start-up stems from a collaboration between Frazier Healthcare and Takeda, and aims to continue the development of HIL-214, a promising virus-like particle vaccine candidate for norovirus that is now in Phase II clinical trials. H Product Launches
Microbioz India, February 2024 | 54 The company is currently in the process of establishing its laboratory to advance HIL-214 development, and is thrilled to have won the ‘INTEGRA supports start-ups’ competition. Dr Erika Olson, Senior Scientist in the company’s Clinical Assay Group, explained: “I have always had great experiences working with INTEGRA products in the past; the pipettes are ergonomic, easy to program, and work beautifully every time. Having access to a broad pipetting volume range will help to ensure that we obtain the highest efficiency and quality of results, and the GRIPTIPS give us confidence that the tips are securely attached. In addition, the ability of EVOLVE pipettes to switch from the lowest to the highest volume in just a few clicks is a very unique aspect that – along with the lightweight design and low tip attachment and ejection forces – significantly improves ergonomics to reduce repetitive strain injuries. We are really excited to get started and put the pipettes to work.” Read more about HilleVax and how it will use INTEGRA’s liquid handling solutions. About INTEGRA Biosciences INTEGRA Biosciences is a leading provider of high-quality laboratory tools and consumables for liquid handling and media preparation. The company is committed to creating innovative solutions which fulfil the needs of its customers in research, diagnostics and quality control within the life sciences markets and medical sector. Today, INTEGRA innovative laboratory products are widely used all around the world. More than 100 distribution partners form a worldwide sales network providing responsive and competent services to customers. These distribution partners are supported by a highly motivated and experienced team of specialists at the company headquarters in Zizers, Switzerland and Hudson, NH, USA. INTEGRA is an ISO 9001 certified company. Secure your place on the BioLC Workshop now! Story source/Credit: YMC Europe GmbH Learn relevant information about advanced separation and detection techniques in antibody and peptide/protein analysis - from theory to practical application. eepen your knowledge in this exciting workshop designed specifically for bio chromatography users. Gain a comprehensive insight into the latest trends and methods in the chromatographic analysis of antibodies, proteins and peptides. You will receive important background information and valuable tips for practical application from experienced workers in biopharmaceutical research and development as well as experienced specialists in (U)HPLC separations and detectors. This comprehensive workshop will be hosted by YMC Europe in cooperation with the renowned Institute for Energy & Environment, Technology & Analytics e.V. (IUTA) in Duisburg, Germany, on 24 September 2024. The language will be German. D Product Launches
Microbioz India, February 2024 | 55
Microbioz India, February 2024 | 56 SPT Labtech delivers endto-end automated NGS library preparation with firefly+ Story source/Credit: SPT Labtech Ltd firefly®+ sets a new efficiency standard in genomics by delivering maximum walkaway time in a compact and intuitive benchtop instrument PT Labtech, a global leader in the design, development and manufacture of automated instrumentation and consumables for life science applications, announces the release of firefly®+, an expansion to its established firefly genomics liquid handling platform, integrating an on-deck thermocycler and increased labware capacity to enable complete hands-free NextGeneration Sequencing (NGS) library preparation. These additional capabilities build on the strong foundation of the firefly platform, which incorporates technologies of multiple instruments, including modules for pipetting, dispensing, shaking and incubating. An internal robotic gripper ensures seamless transfer between all functionalities without the need for manual intervention, granting scientists more walkaway time to focus on critical tasks such as data analysis and experiment design. Central to firefly’s development is its compact design and usability. Unlike traditional liquid handlers, firefly+ offers the benefits of integrated automation without the need for extensive lab space or specialized programming knowledge. The complete system occupies just over one meter in width and sits comfortably on a standard lab bench. Its operation is powered by firefly’s visual and intuitive software that makes protocol development, execution and sharing effortlessly straightforward. With firefly+, researchers maintain full access to firefly’s liquid handling and process modules capabilities even while the thermocycler is in operation. This versatility caters to different laboratory challenges, offering unparalleled freedom and efficiency in genomics workflows. "With this newest development, we’ve added even more functionality whilst retaining firefly’s signature compact footprint and standardized architecture, so labs don’t need to sacrifice premium lab space to achieve complete end-to-end automation,” says Paul Lomax, Head of Genomics at SPT Labtech. “firefly+ is a testament to SPT Labtech’s commitment to customer-driven innovation to advance genomics research. After actively engaging with the scientific community and understanding their real-world challenges, we have developed a solution that offers complete versatility to support labs of different sizes, applications and throughput requirements. By decoupling firefly+ from firefly’s existing liquid handling capabilities, we’re providing genomics scientists with the freedom and tools to reach maximum efficiency.” About SPT Labtech SPT Labtech makes products that transform the way scientists work. For nearly two decades, our expert scientists, engineers, and business innovators have created innovative solutions for liquid handling, sample preparation and management that help accelerate research and make a real difference to human health. We work collaboratively with our customers, building trusted relationships that enable us to deliver exceptional, personalized experiences designed for real world challenges in the lab. S Product Launches
Microbioz India, February 2024 | 57 Agilent Announces New ProteoAnalyzer System Story source/Credit: Agilent Technologies Automated parallel capillary electrophoresis system simplifies protein analysis gilent Technologies Inc. has announced the release of a new automated parallel capillary electrophoresis system for protein analysis – the Agilent ProteoAnalyzer system – at the 23rd Annual PepTalk Conference, held January 16-19 in San Diego. This new platform simplifies and improves the efficiency of analyzing complex protein mixtures, a process central to analytical workflows across the pharma, biotech, food analysis, and academia sectors. Capillary electrophoresis (CE) has established itself as an indispensable tool for protein separation, as it offers rapid, high-resolution analysis with minimal sample consumption. The expanding interest of biopharma in monoclonal antibodies and other protein targets of potential therapeutic interest is driving the expected growth in demand for CE solutions. The Agilent ProteoAnalyzer system brings added efficiency, versatility, and reliability, particularly in protein QC workflows. Automating the separation, data processing, and simplifying sample preparation steps streamlines the analysis workflow, which improves efficiency and reduces training and related labor costs. The system also can analyze a wide range of sample types, from crude lysates to purified fractions. It can analyze different sizes and types of proteins in a single run and consistently deliver accurate results, reducing the need for time-consuming and costly reanalysis. “The Agilent ProteoAnalyzer system introduces a new level of efficiency, versatility, and reliability to protein analysis,” commented Knut Wintergerst, vice president and general manager of the Biomolecular Analysis Division at Agilent. “Automated parallel capillary electrophoresis simplifies the analysis of complex mixtures, benefiting diverse sectors from pharma to academia. Precision and reliability converge, reducing labor costs and enhancing analytical workflows.” Agilent, one of the market leaders in CE, offers automated electrophoresis systems that see wide use for nucleic acids analysis, such as NGS QC and IVT RNA applications. Agilent expects the ProteoAnalyzer to strengthen its position as a key provider of quality control analysis solutions by extending its CE portfolio across relevant biomolecule classes. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook. A Product Launches
Microbioz India, February 2024 | 58
Microbioz India, February 2024 | 59
Microbioz India, February 2024 | 60 PUBLISHED ON: 25th February 2024 RNI NUMBER: UPENG/2017/73675